At 11:30 AM in Hall 5: IMS/IMWG Consensus Update. #IMS26
@myeloma-society.bsky.social
@myeloma-society.bsky.socialAt 11:30 AM in Hall 5: IMS/IMWG Consensus Update. #IMS26
@mskdeptofmed.bsky.socialComing up at #IMS26: Dr. Neha Korde will present phase 1/2 trial results on alternating daratumumab-RVD and teclistamab-RVD in transplant-eligible, standard-risk newly diagnosed multiple myeloma.
🗓️ Wednesday, September 23
🕛 12 p.m. BT (7 a.m. ET)
@mskcancercenter.bsky.social
@myeloma-society.bsky.socialAt 10:00 AM in Hall 5: Newly Diagnosed Multiple Myeloma. #IMS26
@targetedonc.bsky.socialWe've landed in Glasgow and are ready for day 1 of #IMS26! Stay tuned this week for updates, interviews, and more from our team on the ground!
@myeloma-society.bsky.socialWelcome to Day 1 of #IMS26. Join us for breakfast at 7:15 AM during the Industry Symposium Supported by GSK, followed by the Opening Ceremony and Keynote. View today's program: bit.ly/4h7Tm8H
@myeloma-society.bsky.socialHere’s a first look at #IMS26. 👀 We look forward to welcoming you tomorrow morning!
@myeloma-society.bsky.socialStop by Booth 1353 during #IMS26 to learn more about IMS membership and upcoming events. Still need to register? bit.ly/4cdFJkH
@myeloma-society.bsky.socialRegister for #IMS26 wherever you are!📱💻Join us in Glasgow, September 23–26, to connect with global leaders in myeloma research and care.➡️ bit.ly/4cdFJkH
@myeloma-society.bsky.socialExpert perspectives. Real-world insights. A must-attend session at #IMS26 ➡️bit.ly/4cdFJkH
@myeloma-society.bsky.social❓How do you treat first relapse? Hear experts discuss how evolving evidence is transforming treatment approaches in early relapsed myeloma at #IMS26. ➡️ http://bit.ly/4cdFJkH
